NE-DESIGN-DATA
23.5.2017 14:02:47 CEST | Business Wire | Press release
Design Data, a leader in 3D steel detailing and Building Information Modeling (BIM) software, announced that the Steel Construction Institute (SCI) has recently assessed Design Data’s SDS/2 2016 software for connection design.
SDS/2 takes a uniquely intelligent approach in its connection design by considering framing conditions and erectability, automatically performing clash prevention as a part of its connection design. In addition, SDS/2 can value engineer the connections on a project, helping users to design the most economical connections to fabricate and erect.
SCI’s process involved reviewing connection design output in depth for each connection type: partial depth end plates, fin plates, column splices, beam splices, bracing connections, and bolted moment connections (end plates). Each connection was reviewed in detail for numerical correctness for the specific arrangement, but also to demonstrate that important principles common to all connections were correctly implemented.
SCI’s assessment was made in accordance with Eurocode 3: Design of steel structures, BS EN 1993, and the relevant UK National Annexes. Additionally, the “Green Books” were used as reference documents, being referenced in the U.K. National Annex and the de facto standard in the U.K.
“Achieving SCI Assessed status is a key advantage for us entering the U.K. and European markets,” said Damon Scaggs, president of Design Data. “With incorporating European design codes for the first time into SDS/2 — which already implements American, Canadian and Australian design codes — it was important to subject the software to the rigorous and extensive testing SCI conducted. This will help give our new European customers the confidence in our connections that our customers around the world have had for more than 30 years.”
According to the SCI Assessed website, “SCI Assessed” is an established quality mark that is awarded to testify that manufacturers' technical data has been independently verified by SCI. The scheme provides reliability for the range of performance data offered by suppliers particularly where, for example, the product is new or the values are based on calculation methods outside the scope of established standards.
About Design Data
Design Data, a Nemetschek company, is a leading software innovator for the steel industry's fabrication, detailing and engineering sectors. SDS/2 software products provide automatic connection optimization, detailing, engineering information, fabrication data and much more, reducing the time required to design, detail, fabricate and erect steel. Founded in 1981 and headquartered in Lincoln, Nebraska, USA, the company serves customers in 17 countries. Information on Design Data and SDS/2 can be found at: www.sds2.com .
About SCI
SCI has been a trusted, independent source of information and engineering expertise globally for over 30 years, and remains the leading, independent provider of technical expertise and disseminator of best practice to the steel construction sector. SCI offers comprehensive advice, technical information, consultancy services and membership for manufacturers, engineers and designers for every aspect of steel construction.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170523005367/en/
Contact:
Design Data
Damon Scaggs, 402-441-4000
President
Fax:
402-441-4045
damon@sds2.com
www.sds2.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
